Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically ...
Advanced Encryption Standard supplants the Data Encryption Standard and Triple-DES to strengthen security and boost efficiency. Adopted in 1977 as Federal Information Processing Standard (FIPS) ...
BOSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
(p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically meaningful functional improvements (p ≤ 0.002) Patients in the RADIANT study of vormatrigine showed rapid, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback